Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.78 USD | -1.81% | +6.61% | +60.73% |
Financials (USD)
Sales 2024 * | 15.95B | Sales 2025 * | 16.52B | Capitalization | 19.36B |
---|---|---|---|---|---|
Net income 2024 * | 820M | Net income 2025 * | 1.39B | EV / Sales 2024 * | 2.15 x |
Net Debt 2024 * | 14.93B | Net Debt 2025 * | 12.41B | EV / Sales 2025 * | 1.92 x |
P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
12.7
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.71% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 day | -1.81% | ||
1 week | +6.61% | ||
Current month | +19.43% | ||
1 month | +26.83% | ||
3 months | +27.12% | ||
6 months | +87.28% | ||
Current year | +60.73% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 59 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.38% | 13 M€ | -.--% | ||
0.27% | 17 M€ | +7.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 16.78 | -1.81% | 12,697,642 |
24-05-14 | 17.09 | +1.24% | 14,462,634 |
24-05-13 | 16.88 | +3.88% | 18,576,436 |
24-05-10 | 16.25 | +1.56% | 13,820,259 |
24-05-09 | 16 | +1.65% | 16,780,250 |
Delayed Quote Nyse, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.73% | 19.36B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- TEVA Stock